Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After Second-line Treatment — StellaPhase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations(2 sites)
China
First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi The First Hospital of Nanchang, Nanchang, Jiangxi Last updated December 2024